Literature DB >> 28176217

Can MDCT or EUS features predict the histopathological grading scheme of pancreatic neuroendocrine neoplasms?

Hui Zhu1,2, Lang Ying3, Wei Tang1,2, Xiujiang Yang2,4, Bo Sun5,6.   

Abstract

PURPOSE: To identify whether the features of preoperative MDCT or EUS could predict the histopathological grading scheme of pancreatic neuroendocrine neoplasms (pNENs).
METHODS: A total of 25 patients with pNENs were enrolled in the present study. The qualitative and quantitative variables were reviewed. The qualitative variables included location, contour, border, necrosis, intratumoral vessel, homogeneity, calcification, peripancreatic fat/vessel infiltration, pancreatic duct dilatation, mass within pancreas, lymphadenopathy and hepatic metastasis on MDCT and border, echogenicity, cystic/solid and blood flow on EUS. The quantitative variables included long diameter (LD), short diameter (SD), unenhanced mass attenuation (UMA), unenhanced pancreatic attenuation (UPA), arterial phase mass attenuation (APMA), arterial phase pancreatic attenuation (APPA), portal venous phase mass attenuation (PVPMA), portal venous phase pancreatic attenuation (PVPPA), arterial phase enhancement degree (APED) and portal venous phase enhancement degree (PVPED). In addition, sex and age were also evaluated. Histopathological classifications met the criterion of 2010 edition WHO Histopathological Classifications. Kruskal-Wallis test and Boruta algorithm were conducted.
RESULTS: Lymphadenopathy and peripancreatic fat or vascular invasion foretold higher histopathological grading level while well-defined border on EUS image lower grading level.
CONCLUSIONS: Lymphadenopathy, border on EUS image and peripancreatic fat or vascular invasion can predict the histopathological grading scheme of pNENs.

Entities:  

Keywords:  Endosonography; Multi-detector computed tomography (MDCT); Pancreatic neuroendocrine neoplasms; Pathological classification; Prognosis

Mesh:

Year:  2017        PMID: 28176217     DOI: 10.1007/s11547-017-0727-9

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  28 in total

1.  ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors.

Authors:  Massimo Falconi; Detlef Klaus Bartsch; Barbro Eriksson; Günter Klöppel; José M Lopes; Juan M O'Connor; Ramón Salazar; Babs G Taal; Marie Pierre Vullierme; Dermot O'Toole
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

2.  Intravoxel incoherent motion diffusion-weighted imaging of pancreatic neuroendocrine tumors: prediction of the histologic grade using pure diffusion coefficient and tumor size.

Authors:  Eui Jin Hwang; Jeong Min Lee; Jeong Hee Yoon; Jung Hoon Kim; Joon Koo Han; Byung Ihn Choi; Kyoung-Bun Lee; Jin-Young Jang; Sun-Whe Kim; Marcel Dominik Nickel; Berthold Kiefer
Journal:  Invest Radiol       Date:  2014-06       Impact factor: 6.016

3.  Cystic pancreatic neuroendocrine tumors: endoscopic ultrasound and fine-needle aspiration characteristics.

Authors:  W J Yoon; E S Daglilar; M B Pitman; W R Brugge
Journal:  Endoscopy       Date:  2013-01-07       Impact factor: 10.093

4.  Pancreatic neuroendocrine tumours: correlation between MSCT features and pathological classification.

Authors:  Yanji Luo; Zhi Dong; Jie Chen; Tao Chan; Yuan Lin; Minhu Chen; Zi-Ping Li; Shi-Ting Feng
Journal:  Eur Radiol       Date:  2014-07-22       Impact factor: 5.315

5.  Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study.

Authors:  Alberto Larghi; Gabriele Capurso; Antonella Carnuccio; Riccardo Ricci; Sergio Alfieri; Domenico Galasso; Francesca Lugli; Antonio Bianchi; Francesco Panzuto; Laura De Marinis; Massimo Falconi; Gianfranco Delle Fave; Giovanni Battista Doglietto; Guido Costamagna; Guido Rindi
Journal:  Gastrointest Endosc       Date:  2012-09       Impact factor: 9.427

Review 6.  Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: a meta-analysis.

Authors:  Paul D James; Apostolos V Tsolakis; Mei Zhang; Paul J Belletrutti; Rachid Mohamed; Derek J Roberts; Steven J Heitman
Journal:  Gastrointest Endosc       Date:  2015-04       Impact factor: 9.427

7.  EUS for pancreatic neuroendocrine tumors: a single-center, 11-year experience.

Authors:  Shireen A Pais; Mohammad Al-Haddad; Mehdi Mohamadnejad; Julia K Leblanc; Stuart Sherman; Lee McHenry; John M DeWitt
Journal:  Gastrointest Endosc       Date:  2010-03-20       Impact factor: 9.427

8.  Incidental neuroendocrine tumors of the pancreas: MDCT findings and features of malignancy.

Authors:  Anna Gallotti; Rocio Perez Johnston; Pietro A Bonaffini; Thun Ingkakul; Vikram Deshpande; Carlos Fernández-del Castillo; Dushyant V Sahani
Journal:  AJR Am J Roentgenol       Date:  2013-02       Impact factor: 3.959

9.  Basing treatment strategy for non-functional pancreatic neuroendocrine tumors on tumor size.

Authors:  Yoji Kishi; Kazuaki Shimada; Satoshi Nara; Minoru Esaki; Nobuyoshi Hiraoka; Tomoo Kosuge
Journal:  Ann Surg Oncol       Date:  2014-04-18       Impact factor: 5.344

10.  The value of gadoxetic acid-enhanced and diffusion-weighted MRI for prediction of grading of pancreatic neuroendocrine tumors.

Authors:  Kyung Mi Jang; Seong Hyun Kim; Soon Jin Lee; Dongil Choi
Journal:  Acta Radiol       Date:  2013-07-29       Impact factor: 1.990

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.